NAVB has been successfully added to your Stock Email Alerts list.
You can manage your stock email alerts here.
NAVB has been removed from your Stock Email Alerts list.
Please enter Portfolio Name for new portfolio.
Navidea Biopharmaceuticals's change in receivables for the quarter that ended in Sep. 2023 was $0.01 Mil. It means Navidea Biopharmaceuticals's Accounts Receivable declined by $0.01 Mil from Jun. 2023 to Sep. 2023 .
Navidea Biopharmaceuticals's change in receivables for the fiscal year that ended in Dec. 2022 was $0.09 Mil. It means Navidea Biopharmaceuticals's Accounts Receivable declined by $0.09 Mil from Dec. 2021 to Dec. 2022 .
Navidea Biopharmaceuticals's Accounts Receivable for the quarter that ended in Sep. 2023 was $0.03 Mil.
Days Sales Outstanding measures of the average number of days that a company takes to collect revenue after a sale has been made. It is a financial ratio that illustrates how well a company's Accounts Receivable are being managed.
In Ben Graham's calculation of liquidation value, Apple Inc's Accounts Receivable are only considered to be worth 75% of book value. Navidea Biopharmaceuticals's liquidation value for the three months ended in Sep. 2023 was $-4.56 Mil.
The historical data trend for Navidea Biopharmaceuticals's Change In Receivables can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Navidea Biopharmaceuticals Annual Data | |||||||||||||||||||||
Trend | Dec13 | Dec14 | Dec15 | Dec16 | Dec17 | Dec18 | Dec19 | Dec20 | Dec21 | Dec22 | |||||||||||
Change In Receivables | Get a 7-Day Free Trial | 12.93 | -0.07 | 0.84 | -0.03 | 0.09 |
Navidea Biopharmaceuticals Quarterly Data | ||||||||||||||||||||
Dec18 | Mar19 | Jun19 | Sep19 | Dec19 | Mar20 | Jun20 | Sep20 | Dec20 | Mar21 | Jun21 | Sep21 | Dec21 | Mar22 | Jun22 | Sep22 | Dec22 | Mar23 | Jun23 | Sep23 | |
Change In Receivables | Get a 7-Day Free Trial | -0.13 | 0.16 | -0.03 | -0.01 | 0.01 |
Change In Accounts Receivable relative to the previous period. It is any increase or decrease in the cash a company is owed by its customers.
Change In Receivables for the trailing twelve months (TTM) ended in Sep. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $0.13 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Navidea Biopharmaceuticals (OTCPK:NAVB) Change In Receivables Explanation
1. Accounts Receivable are created when a customer has received a product but has not yet paid for that product. Days Sales Outstanding measures of the average number of days that a company takes to collect revenue after a sale has been made. It is a financial ratio that illustrates how well a company's Accounts Receivable are being managed.
Navidea Biopharmaceuticals's Days Sales Outstanding for the quarter that ended in Sep. 2023 is calculated as:
Days Sales Outstanding | |||||
= | Accounts Receivable | / | Revenue | * | Days in Period |
= | 0.031 | / | 0 | * | 91 |
= |
2. In Ben Graham's calculation of liquidation value, Navidea Biopharmaceuticals's accounts receivable are only considered to be worth 75% of book value:
Navidea Biopharmaceuticals's liquidation value for the quarter that ended in Sep. 2023 is calculated as:
Liquidation Value | |||||||
= | Cash, Cash Equivalents, Marketable Securities | - | Total Liabilities | + | (0.75 * Accounts Receivable) | + | (0.5 * Total Inventories) |
= | 3.865 | - | 8.679 | + | 0.75 * 0.031 | + | 0.5 * 0.461 |
= | -4.56 |
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Thank you for viewing the detailed overview of Navidea Biopharmaceuticals's Change In Receivables provided by GuruFocus.com. Please click on the following links to see related term pages.
Craig Dais | officer: Chief Financial Officer | 4995 BRADENTON AVENUE, SUITE 240, DUBLILN OH 43017 |
Dana J Moss | director | 4995 BRADENTON AVE, SUITE 240, DUBLIN OH 43017 |
Jill Stefanelli | director | 4995 BRADENTON AVE, SUITE 240, DUBLIN OH 43017 |
Josh M Wilson | director | 4795 BRADENTON AVE, STE 240, DUBLIN OH 43017 |
Scott John K Jr. | director, 10 percent owner | 30 BLUE HERON DR., GREENWOOD VILLAGE CO 80121 |
Agnieszka Winkler | director | C/O INTER-TEL, INCORPORATED, 1615 SOUTH 52ND STREET, TEMPE AZ 85281 |
Thomas F Farb | director | C/O SUMMIT PARTNERS, 222 BERKELEY ST 18TH FL, BOSTON MA 02116 |
Michel Mikhail | officer: Chief Regulatory Officer | 4995 BRADENTON AVE, SUITE 240, DUBLIN OH 43017 |
Malcolm G Witter | director | 4995 BRADENTON AVE, SUITE 240, DUBLIN OH 43017 |
Alexander L Cappello | director | C/O THE CHEESECAKE FACTORY INC, 26901 MALIBU HILLS ROAD, CALABASAS HILLS CA 91301 |
Amit Bhalla | director | 4995 BRADENTON AVE, SUITE 240, DUBLIN OH 43017 |
Joel H. Kaufman | officer: Chief Business Officer | 4995 BRADENTON AVE, SUITE 240, DUBLIN OH 43017 |
Jed Latkin | officer: Interim COO | 152 W. 57TH STREET, 4TH FLOOR, NEW YORK NY 10019 |
Sarah Kathryn Rouan | director | 4995 BRADENTON AVENUE, SUITE 240, DUBLIN OH 43017 |
Claudine Bruck | director | 4995 BRADENTON AVE, SUITE 240, DUBLIN OH 43017-3552 |
From GuruFocus
By GF Value GF Value • 04-06-2021
By PRNewswire PRNewswire • 10-29-2019
By ACCESSWIRE AccessWire • 04-12-2019
By PRNewswire PRNewswire • 05-22-2020
By Monica Wolfe Monica Wolfe • 03-18-2013
By PRNewswire PRNewswire • 05-22-2020
Disclaimers: GuruFocus.com is not operated by a broker or a dealer. It has an affiliated registered investment adviser, which serves as the subadviser to an exchange traded fund. This investment adviser does not provide advice to individual investors. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes provided by InterActive Data. Fundamental company data provided by Morningstar, updated daily.